Incidence of Second Primary Malignancies ...
Document type :
Article dans une revue scientifique
PMID :
Permalink :
Title :
Incidence of Second Primary Malignancies after Autologous Transplantation for Multiple Myeloma in the Era of Novel Agents.
Author(s) :
Sahebi, Firoozeh [Auteur]
Iacobelli, Simona [Auteur]
Sbianchi, Giulia [Auteur]
Koster, Linda [Auteur]
Blaise, Didier [Auteur]
Remenyi, Peter [Auteur]
Russell Nigel, H [Auteur]
Ljungman, Per [Auteur]
Kobbe, Guido [Auteur]
Apperley, Jane [Auteur]
Trneny, Marek [Auteur]
Krejci, Marta [Auteur]
Wiktor-Jedrzejczak, Wieslaw [Auteur]
Sanchez James, F [Auteur]
Schaap, Nicolaas [Auteur]
Isaksson, Cecilia [Auteur]
Lenhoff, Stig [Auteur]
Browne, Paul [Auteur]
Scheid, Christof [Auteur]
Wilson Keith M, O [Auteur]
Yakoub-Agha, Ibrahim [Auteur]
Lille Inflammation Research International Center - U 995 [LIRIC]
Muniz Soledad, Gonzalez [Auteur]
Schonland, Stefan [Auteur]
Morris, Curly [Auteur]
Garderet, Laurent [Auteur]
Kroger, Nicolaus [Auteur]
Iacobelli, Simona [Auteur]
Sbianchi, Giulia [Auteur]
Koster, Linda [Auteur]
Blaise, Didier [Auteur]
Remenyi, Peter [Auteur]
Russell Nigel, H [Auteur]
Ljungman, Per [Auteur]
Kobbe, Guido [Auteur]
Apperley, Jane [Auteur]
Trneny, Marek [Auteur]
Krejci, Marta [Auteur]
Wiktor-Jedrzejczak, Wieslaw [Auteur]
Sanchez James, F [Auteur]
Schaap, Nicolaas [Auteur]
Isaksson, Cecilia [Auteur]
Lenhoff, Stig [Auteur]
Browne, Paul [Auteur]
Scheid, Christof [Auteur]
Wilson Keith M, O [Auteur]
Yakoub-Agha, Ibrahim [Auteur]
Lille Inflammation Research International Center - U 995 [LIRIC]
Muniz Soledad, Gonzalez [Auteur]
Schonland, Stefan [Auteur]
Morris, Curly [Auteur]
Garderet, Laurent [Auteur]
Kroger, Nicolaus [Auteur]
Journal title :
Biology of Blood and Marrow Transplantation
Abbreviated title :
Biol. Blood Marrow Transplant.
Volume number :
24
Pages :
930-936
Publication date :
2018-05
ISSN :
1523-6536
Keyword(s) :
Immunomodulatory drugs
Second primary malignancies
Multiple myeloma
Plerixafor
Proteasome inhibitors
Second primary malignancies
Multiple myeloma
Plerixafor
Proteasome inhibitors
HAL domain(s) :
Sciences du Vivant [q-bio]
English abstract : [en]
The advent of novel agents for multiple myeloma (MM) is cause for a re-examination of the incidence of second primary malignancies (SPMs). We examined the SPM rate in MM patients who were enrolled in the prospective ...
Show more >The advent of novel agents for multiple myeloma (MM) is cause for a re-examination of the incidence of second primary malignancies (SPMs). We examined the SPM rate in MM patients who were enrolled in the prospective observational CALM (Collaboration to Collect Autologous Transplant outcome in Lymphoma and Myeloma) study. Between 2008 and 2012, 3204 patients with MM underwent a first autologous hematopoietic stem cell transplantation. Plerixafor was used as a mobilizing agent for patients with poor (or potentially poor) stem cell mobilization as defined by the respective centers. A total of 135 patients developed SPMs, with a cumulative incidence of 5.3% (95% confidence interval, 4.4 to 6.3) at 72 months. Ninety-four patients developed solid tumors, 30 developed hematologic malignancies, and 11 developed an SPM of an unknown type. The cumulative incidence of known hematologic and solid malignancies were 1.4% and 3.6%, respectively, at 72 months. In a univariate analysis, use of radiotherapy, type of induction regimen, hematopoietic stem cell dose, poor mobilizer status, plerixafor use, and sex did not influence the cumulative incidence of SPMs. Only age over 65 years was statistically associated with an increased incidence. Overall, the incidence of SPMs was comparable to earlier estimations of SPMs in MM.Show less >
Show more >The advent of novel agents for multiple myeloma (MM) is cause for a re-examination of the incidence of second primary malignancies (SPMs). We examined the SPM rate in MM patients who were enrolled in the prospective observational CALM (Collaboration to Collect Autologous Transplant outcome in Lymphoma and Myeloma) study. Between 2008 and 2012, 3204 patients with MM underwent a first autologous hematopoietic stem cell transplantation. Plerixafor was used as a mobilizing agent for patients with poor (or potentially poor) stem cell mobilization as defined by the respective centers. A total of 135 patients developed SPMs, with a cumulative incidence of 5.3% (95% confidence interval, 4.4 to 6.3) at 72 months. Ninety-four patients developed solid tumors, 30 developed hematologic malignancies, and 11 developed an SPM of an unknown type. The cumulative incidence of known hematologic and solid malignancies were 1.4% and 3.6%, respectively, at 72 months. In a univariate analysis, use of radiotherapy, type of induction regimen, hematopoietic stem cell dose, poor mobilizer status, plerixafor use, and sex did not influence the cumulative incidence of SPMs. Only age over 65 years was statistically associated with an increased incidence. Overall, the incidence of SPMs was comparable to earlier estimations of SPMs in MM.Show less >
Language :
Anglais
Audience :
Internationale
Popular science :
Non
Administrative institution(s) :
Inserm
Université de Lille
CHU Lille
Université de Lille
CHU Lille
Research team(s) :
Immunity, inflammation and fibrsis in auto and allo-reactivity
Submission date :
2019-03-01T14:46:28Z
2024-01-30T13:24:19Z
2024-01-30T13:24:19Z